September 27th 2024
A study presented at the American Academy of Pediatrics 2024 National Conference finds children with disabilities in foster care face lower permanency rates and higher mortality risks, calling for specialized support and interventions.
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Study: Ritalin effective in preschoolers with ADHD
October 10th 2005The longest and most complex study of methylphenidate (Ritalin) in preschool children shows that it can be safe and effective for some children in that age group who have attention deficit hyperactive disorder (ADHD), according to the study's lead author.
The question of the day: Is there an autism epidemic?
October 8th 2005The answer? We don't really know, according to Craig Newschaffer, PhD, associate professor at the Johns Hopkins School of Public Health. But fears of an autism epidemic have been overblown by the press and advocacy groups, said Dr. Newschaffer, speaking at the American Academy of Pediatrics National Conference and Exhibition today in Washington, D.C.
FDA extends indication for ADHD treatment formulation to adolescent years
October 5th 2005The US Food and Drug Administration (FDA) recently approved Adderall XR (an extended-release formulation of mixed salts of amphetamine) as a once-daily treatment for attention deficit hyperactivity disorder in adolescents 13 to 17 years old. That action bridges an "indication gap" between earlier approval of the product for patients 6 to 12 years old and for older (18 years) adolescents and adults.
Let's get discussion of what causes autism back on track!
September 1st 2005Lately, I've spent a lot of time talking about the alleged link between thimerosal in pediatric vaccines and autism. Most of you have been asked by parents whether immunizations pose a risk of autism as well, and some parents are so frightened by rumors, press reports, and information on the World Wide Web that they forgo immunizations for their children altogether.
Where we are, and how well we can succeed, at treating ADHD
December 1st 2003At pediatricians' disposal today are numerous formulations of approved medications for ADHD--traditional psychostimulants and newer agents. We also have developed an appreciation of the value of a multipronged approach to this chronic disorder.
"At least it's natural...." Herbs and dietary supplements in ADHD
September 1st 2000Parents increasingly are turning to alternative therapies to manage their child's ADHD. This review of the pharmacology an toxicology of the most popular herbs and dietary supplements for treating ADHD and what the literature shows about their efficacy should help you advise parents.